PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
115.67%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
115.67%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
719.71%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
-133.51%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-132.80%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.